Path-breaking target therapies for lung cancer and a far-sighted health policy to support clinical and cost effectiveness
- 1 March 2014
- journal article
- Published by Elsevier BV in Health Policy and Technology
- Vol. 3 (1), 74-82
- https://doi.org/10.1016/j.hlpt.2013.09.007
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Driving forces of technological change in medicine: Radical innovations induced by side effects and their impact on society and healthcareTechnology in Society, 2012
- Evaluation of the introduction of a diagnosis procedure combination system for patient outcome and hospitalisation charges for patients with hip fracture or lung cancer in JapanHealth Policy, 2012
- Pharmacogenomic biomarkers: new tools in current and future drug therapyTrends in Pharmacological Sciences, 2011
- The effect of the COACH program (Continuity Of Appropriate pharmacotherapy, patient Counselling and information transfer in Healthcare) on readmission rates in a multicultural population of internal medicine patientsBMC Health Services Research, 2010
- Differential patient–caregiver opinions of treatment and care for advanced lung cancer patientsSocial Science & Medicine, 2010
- Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analysesPersonalized Medicine, 2009
- Measuring the impact of sustainable technological innovationInternational Journal of Technology Intelligence and Planning, 2009
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004